A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

137

Participants

Timeline

Start Date

September 20, 2011

Primary Completion Date

November 16, 2015

Study Completion Date

February 18, 2020

Conditions

Lymphoma, Large-Cell, AnaplasticCarcinoma, Non-Small-Cell Lung

Interventions

DRUG

Brigatinib

Brigatinib tablets and capsules.